Autosomal recessive spastic paraplegia type 39

Autosomal recessive spastic paraplegia type 39 (SPG39) is a rare hereditary spastic paraplegia caused by mutations in the PNPLA6 gene (also known as NTE, neuropathy target esterase), located on chromosome 19p13.2. This gene encodes an enzyme involved in phospholipid metabolism that is critical for maintaining the integrity of neuronal membranes and axonal transport. SPG39 is also referred to as neuropathy target esterase-related spastic paraplegia. The disease primarily affects the nervous system, specifically the upper motor neurons of the corticospinal tract and peripheral nerves. Key clinical features include progressive spasticity and weakness of the lower limbs, which typically begins in childhood. Patients may also develop upper limb involvement over time, along with distal muscle wasting and peripheral neuropathy. The combination of upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron features (muscle atrophy, reduced reflexes distally) reflects the complex nature of this condition. Cognitive function is generally preserved. There is currently no cure or disease-modifying therapy for SPG39. Management is supportive and symptomatic, focusing on physical therapy and rehabilitation to maintain mobility, antispasticity medications (such as baclofen or tizanidine) to manage muscle stiffness, and orthopedic interventions as needed. Occupational therapy may help patients maintain independence in daily activities. Regular neurological follow-up is recommended to monitor disease progression and adjust treatment strategies accordingly.

Common questions about Autosomal recessive spastic paraplegia type 39